Literature DB >> 30190824

Immunohistochemistry for an improved clinical workflow in the era of personalized melanoma therapy?

Daniela Massi1, Mario Mandalà1,1.   

Abstract

Entities:  

Keywords:  BRAF; NRAS; immunohistochemistry; mutation

Year:  2015        PMID： 30190824      PMCID： PMC6094605          DOI： 10.2217/mmt.14.27

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  19 in total

1.  NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Authors:  John A Jakob; Roland L Bassett; Chaan S Ng; Jonathan L Curry; Richard W Joseph; Gladys C Alvarado; Michelle L Rohlfs; Jessie Richard; Jeffrey E Gershenwald; Kevin B Kim; Alexander J Lazar; Patrick Hwu; Michael A Davies
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

2.  Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility.

Authors:  Cristi Marin; Alain Beauchet; David Capper; Ute Zimmermann; Catherine Julié; Marius Ilie; Philippe Saiag; Andreas von Deimling; Paul Hofman; Jean-François Emile
Journal:  Arch Pathol Lab Med       Date:  2013-05-07       Impact factor: 5.534

Review 3.  Nras in melanoma: targeting the undruggable target.

Authors:  Mario Mandalà; Barbara Merelli; Daniela Massi
Journal:  Crit Rev Oncol Hematol       Date:  2014-06-12       Impact factor: 6.312

4.  Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

Authors:  Georgina V Long; James S Wilmott; David Capper; Matthias Preusser; Yuxiao E Zhang; John F Thompson; Richard F Kefford; Andreas von Deimling; Richard A Scolyer
Journal:  Am J Surg Pathol       Date:  2013-01       Impact factor: 6.394

5.  The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.

Authors:  Xiaofeng Jiang; Jun Zhou; Anita Giobbie-Hurder; Jennifer Wargo; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2012-10-24       Impact factor: 12.531

6.  Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.

Authors:  Klaus J Busam; Cyrus Hedvat; Melissa Pulitzer; Andreas von Deimling; Achim A Jungbluth
Journal:  Am J Surg Pathol       Date:  2013-03       Impact factor: 6.394

7.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

8.  BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.

Authors:  J S Wilmott; A M Menzies; L E Haydu; D Capper; M Preusser; Y E Zhang; J F Thompson; R F Kefford; A von Deimling; R A Scolyer; G V Long
Journal:  Br J Cancer       Date:  2013-02-12       Impact factor: 7.640

9.  Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.

Authors:  Lucile Boursault; Véronique Haddad; Béatrice Vergier; David Cappellen; Severine Verdon; Jean-Pierre Bellocq; Thomas Jouary; Jean-Philippe Merlio
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

10.  Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.

Authors:  Michelle V Pearlstein; Daniel C Zedek; David W Ollila; Amanda Treece; Margaret L Gulley; Pamela A Groben; Nancy E Thomas
Journal:  J Cutan Pathol       Date:  2014-07-04       Impact factor: 1.587
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.